These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 27863353

  • 1. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y, Li C, Zhang RY, Zhang Q, Shen WF, Ding FH, Lu L.
    Int J Cardiol; 2017 Feb 01; 228():129-136. PubMed ID: 27863353
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K, Li YJ, Gao S.
    Coron Artery Dis; 2015 May 01; 26(3):220-4. PubMed ID: 25647458
    [Abstract] [Full Text] [Related]

  • 4. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, Chan SP, Xu HF, Yang XJ.
    Coron Artery Dis; 2015 Jan 01; 26(1):5-10. PubMed ID: 25211654
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.
    Yang L, Zhu H, Sun Y, Yan P, Song X, Xu F, Yuan H, Chen L.
    Clin Cardiol; 2022 Mar 01; 45(3):308-314. PubMed ID: 35032135
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M, Schröder J, Pross V, Marx N, Hoffmann R.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):881-7. PubMed ID: 23765557
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M, Pross V, Marx N, Hoffmann R.
    Coron Artery Dis; 2012 Nov 01; 23(7):492-6. PubMed ID: 22990414
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
    Kastl SP, Katsaros KM, Krychtiuk KA, Jägersberger G, Kaun C, Huber K, Wojta J, Speidl WS.
    PLoS One; 2020 Nov 01; 15(5):e0232483. PubMed ID: 32392256
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T, Fu Y, Wang Y, Li W, Zhao J, Wang X, Wang H, Zhao Y, Fu X.
    BMC Cardiovasc Disord; 2021 Jan 07; 21(1):24. PubMed ID: 33413149
    [Abstract] [Full Text] [Related]

  • 18. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y, Liu K, Chen M, Liu Y, Gao A, Hu C, Li H, Zhu H, Han H, Zhang J, Zhao Y.
    Cardiovasc Diabetol; 2021 Jul 08; 20(1):137. PubMed ID: 34238294
    [Abstract] [Full Text] [Related]

  • 19. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H, Wöhrle J, Brachmann J, Hohenforst-Schmidt W, Schlundt C, Lonke S, von Cranach M, Markovic S, Achenbach S, Waliszewski M.
    Catheter Cardiovasc Interv; 2016 Oct 08; 88(4):529-534. PubMed ID: 26893095
    [Abstract] [Full Text] [Related]

  • 20. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Redfors B, Généreux P, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, Kirtane AJ, Stone GW.
    Am Heart J; 2018 Mar 08; 197():142-149. PubMed ID: 29447774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.